C61
Conditions
Interventions
Group 1: For this project, we plan to analyse MRI data in total of 120 patients with mpMRI and subsequent targeted plus systematic biopsy from the different study sites (Düsseldorf and Herne). The dat
Sponsors
Universitätsklinikum Düsseldorf
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: • Consecutive patients who have received a multiparametric MRI examination at the different study sites and subsequent MRI targeted fusion biopsy. • PI-RADS 1-3 cases with negative systematic biopsy and/or cancer free follow-up
Exclusion criteria
Exclusion criteria: • Non-interpretable examinations (PI-QUAL 1). • Patients who have undergone surgery or radiotherapy for prostate cancer. • Discrepancies and incorrect MR report (filtered out by expert)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint is the diagnosis of clinically significant prostate cancers (csPC) (ISUP = 2) (PI-RADS =3) with histopathological results from consecutive biopsy as the gold standard. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are the number of diagnosed csPC compared to PI-RADS classification. | — |
Countries
Germany
Contacts
Public ContactMatthias Boschheidgen
Universitätsklinikum Düsseldorf
Outcome results
None listed